PYC Therapeutics
8
3
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.5%
1 terminated/withdrawn out of 8 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
Role: lead
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
Role: lead
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
Role: lead
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
Role: lead
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
Role: lead
SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)
Role: lead
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Role: lead
Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
Role: lead
All 8 trials loaded